U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07189065) titled 'A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma' on Sept. 16.
Brief Summary: This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention:
DRUG: Rocbrutinib
200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc.
DRUG: Bendamustine
Partic...